Autoimmunity 3

B cell responses can sometimes malfunction, leading to autoimmune conditions.
The most prevalent autoimmune disease stemming from B cell dysfunction is Systemic Lupus Erythematosus (SLE), commonly referred to as lupus.

Normal function of B cells: In healthy individuals, B cells that produce antibodies against self-proteins are eliminated through a process designed to prevent autoimmunity.
Dysfunction in SLE: In patients with SLE, this elimination does not occur effectively, allowing self-reactive B cells to survive and proliferate.
Antibodies produced by dysfunctional B cells: These B cells may generate antibodies targeting nuclear components, including:
- DNA
- RNA
- Histones
Increased B cell populations: SLE patients exhibit an abundance of B cells and memory cells that have a lower activation threshold, leading to a higher output of self-reactive antibodies. This phenomenon is characterized as B cell-driven autoimmunity.

When self-reactive antibodies bind to their antigens, they are deposited in various organs, particularly the kidneys and joints.
- This deposition can lead to significant health complications, necessitating kidney transplants in approximately 20% of SLE patients.

New research indicates that Xist (X-inactive specific transcript) ribonucleoproteins are influential in promoting female-biased autoimmunity.
Transgenic mouse models show that:
- Inducible expression of Xist in male animals leads to the production of autoantibodies and various autoimmune pathologies.
- Xist expression alters T and B cell populations to mirror female patterns.
- Patients with autoimmune diseases display significant autoantibodies directed against Xist RNP components.

The XX sex chromosome composition is closely linked to heightened vulnerability to autoimmunity in females.
Xist long non-coding RNA participates in random inactivation of one X chromosome, a process crucial for gene dosage regulation.
In male models, the expression of Xist led to the introduction of autoantibody-producing ribonucleoprotein complexes, resulting in multi-organ pathology.

Some autoimmune conditions, like Multiple Sclerosis (MS) and Rheumatoid Arthritis (RA), are characterized by dysfunctional collaboration between B and T cells.

B cells contribute to autoimmunity through various mechanisms:
- Formation of lymphoid follicles and ectopic germinal centers in the central nervous system (CNS).
- Infiltration of pathogenic B cell subsets into the CNS across the blood-brain barrier.
- Ineffective inhibition of effector T cells, leading to maladaptive immune responses.
- Differentiation of memory B cells into plasma cells that secrete oligoclonal immunoglobulins.
- Antigen presentation that activates CD4 T cells.
These interactions lead to secretion of pro-inflammatory cytokines, such as:
- TNF-alpha
- IL-6
- GM-CSF
The role of cytokines in activating CNS cells such as astrocytes and microglia is notable.

Understanding how both T and B cells can target host tissues and the mechanisms usually responsible for switching off these responses.
Differentiating between central tolerance (the body's mechanism to prevent autoimmunity during development) and peripheral tolerance (the maintenance of self-tolerance in mature T and B cells).
Gaining insight into the common autoimmune diseases and appreciating current treatment strategies for these conditions.

Steroids: Used for symptomatic relief but may cause immunosuppression.
Symptomatic treatments: For example, insulin for diabetes management.
Anergic strategies: Inducing anergy in T cells by blocking co-stimulation.
Shutting off T cell activation: Through agents like PD-1 and CTLA4 blockers.
Suppressive cytokines: Or inhibiting the synthesis of pro-inflammatory cytokines.
Infusion of regulatory T cells (Treg): To suppress autoimmune responses.

Crohn's disease is a relapsing inflammatory bowel condition characterized by:
- Severe inflammation primarily affecting the ileum and colon.
- Symptoms including diarrhea, abdominal pain, and risk of damage to the epithelial lining, which might necessitate surgical intervention.

The specific initiation of inflammation is unclear, potentially involving:
- Genetic predispositions.
- Microbial imbalances.
- Environmental factors.
- Inherent dysregulations in immune responses.
T Cells Involvement: Th1 and Th17 cells play critical roles in sustaining inflammatory responses and contribute significantly to tissue damage in affected patients.

Utilized for short-term relief during disease flare-ups.
Mechanism of Action: Induce lymphocyte apoptosis and decrease T cell activation and cytokine secretion.
Caution: System-wide immune suppression can lead to major side effects.

Anti-TNF Therapies (e.g., Infliximab): Transformative in maintaining disease remission by blocking TNF, the principal pro-inflammatory cytokine.
- Caveat: Non-specific TNF blockade increases risk of severe infections, including tuberculosis.

Development of therapies to address specific pathophysiological mechanisms in IBD:
- Modulating T cell activation paths, inhibiting detrimental cytokines, and targeting unique markers on pathogenic immune cells.
For example, preventing naive T lymphocytes from differentiating into Th cells through various inhibitors, like anti-IL-23 mAbs and anti-IL-6 mAbs.

Inhibition by α4β7 blockers (Vedolizumab): Blocks T cells from entering the gut, with fewer side effects compared to systemic therapies. However, only about 50% of patients respond to this treatment.
Exploration of target markers specific to pathogenic T cells continues.

Ongoing efforts focus on identifying specific populations of auto-reactive T cells or triggers that drive their activity. The aim is to inhibit these pathogenic cells while preserving the majority of protective immune functions.
Researchers are also working on minimizing the number of non-responders to treatments and extending the duration of response to therapies.

Autoimmune diseases involve complex and dysregulated cellular responses, including T cells, B cells, and neutrophils.
It remains a challenge to design therapeutic agents that selectively eliminate harmful cell subsets while maintaining the immune system's ability to respond to infections and vaccinations.